Skip to main content

Table 3 Characteristics of the patients stratified according to the KL-6 predictive cut-off for disease progression (N=33)

From: Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis

 

KL-6 <1526 U/mL

KL-6 ≥1526 U/mL

p

(N or mean ± SE)

(N or mean ± SE)

Gender (M/F)

9/10

9/5

ns*

Age (yrs)

52±10

46±11

ns**

Smoking history (yes/no)

15/4

12/2

ns*

Clinical course

   

  -PAP-related death (yes/no)

0/19

2/12

ns*

  -disease progression (yes/no)

3/16

13/1

<0.0001*

Treatment (yes/no)

6/13

12/2

0.03*

  -cumulative number of WLL

3.5±3

7±6.5

0.06

PaO2 (mmHg)

78±14

66±12

0.012**

A-aDO2 (mmHg)

31±12

42±14

0.023**

VC (% pred)

88±15

72±14

0.002**

FEV1 (% pred)

81±15

67±14

0.009**

TLC (% pred)

86±17

72±16

0.017**

DLCO (% pred)

70±15

42±12

<0.0001**

GM-CSF autoantibody (μg/mL)

44±19

55±13

ns**

KL-6 (U/mL)

930±352

3934±1756

<0.0001**

LDH (IU/L)

244±78

327±109

ns**

CEA (ng/mL)

5.5±3.8

7.5±6

ns**

  1. Unless otherwise indicated, values are expressed as mean ± SD (range).
  2. ns= not significant.
  3. * Fischer´ s exact test.
  4. **Student´ s t-test.